How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cyclodextrins in Pharma Market
- By Type of Cyclodextrin: Alpha-Cyclodextrin, Beta-Cyclodextrin, Gamma-Cyclodextrin, Hydroxypropyl Beta-Cyclodextrin, Sulfobutylether Beta-Cyclodextrin
- By Application: Drug Solubilization, Drug Stabilization, Taste Masking, Controlled Drug Release, Drug Delivery Enhancement
- By Route of Administration: Oral, Parenteral, Topical, Ophthalmic, Nasal
- By Therapeutic Area: Oncology, Cardiovascular, Neurology, Infectious Diseases, Respiratory
- By Formulation Type: Solid Dosage Forms, Liquid Dosage Forms, Injectables, Topical Formulations, Ophthalmic Preparations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Alpha-Cyclodextrin leads By Type of Cyclodextrin at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Cyclodextrins in Pharma Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Type of Cyclodextrin 5
Application 5
Route of Administration 5
Therapeutic Area 5
Formulation Type 5
Companies profiled
Wacker Chemie AG
Jungbunzlauer Suisse AG
Roquette Frères
Takasago International Corporation
Cyclolab Ltd.
Ashland Global Holdings Inc.
Hubei Biocause Pharmaceutical Co. Ltd.
Jinan Haohua Industry Co. Ltd.
Shandong Binzhou Zhiyuan Biotechnology Co. Ltd.
Nippon Shokubai Co. Ltd.
Jiangsu Jiuding New Materials Co. Ltd.
Zhejiang NHU Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Wacker Chemie AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Jungbunzlauer Suisse AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roquette Frères
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Takasago International Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cyclolab Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Ashland Global Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Hubei Biocause Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Jinan Haohua Industry Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Shandong Binzhou Zhiyuan Biotechnology Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Nippon Shokubai Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Jiangsu Jiuding New Materials Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Zhejiang NHU Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Hangzhou Dayangchem Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Wuxi Tianlong Technology Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Hunan Nutramax Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,665M by 2033 · 4.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Alpha-Cyclodextrin46.2
- Beta-Cyclodextrin14.4
- Gamma-Cyclodextrin18.7
- Hydroxypropyl Beta-Cyclodextrin10.7
- Sulfobutylether Beta-Cyclodextrin10.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$601.8M → $923.9M · 5.5%
Europe$419.5M → $620.2M · 5.0%
Asia Pacific$383.0M → $562.3M · 4.9%
Latin America$237.1M → $320.9M · 3.9%
Middle East and Africa$182.4M → $249.1M · 4.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.812026
4.812027
4.832028
4.852029
4.842030
4.872031
4.892032
4.882033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Wacker Chemie AG14.4
- Jungbunzlauer Suisse AG18.8
- Roquette Frères9.4
- Takasago International Corporation9.1
- Cyclolab Ltd.7.4
- Ashland Global Holdings Inc.13.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Type of Cyclodextrin28.2%
Application17.5%
Route of Administration12.3%
Therapeutic Area20.8%
Formulation Type21.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.5
- Europe23.2
- Asia Pacific21.0
- Latin America12.0
- Middle East and Africa9.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Wacker Chemie AG | 96 | 93 | 90 | 99 | 79 | 78 | 89 |
| Jungbunzlauer Suisse AG | 88 | 82 | 82 | 77 | 80 | 88 | 83 |
| Roquette Frères | 81 | 69 | 67 | 84 | 88 | 77 | 78 |
| Takasago International Corporation | 77 | 59 | 62 | 73 | 79 | 60 | 68 |
| Cyclolab Ltd. | 65 | 64 | 53 | 71 | 57 | 75 | 64 |
| Ashland Global Holdings Inc. | 51 | 55 | 67 | 57 | 66 | 64 | 60 |
| Hubei Biocause Pharmaceutical Co. Ltd. | 53 | 43 | 44 | 53 | 43 | 51 | 48 |
| Jinan Haohua Industry Co. Ltd. | 46 | 53 | 54 | 45 | 57 | 38 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Wacker Chemie AG
- Jungbunzlauer Suisse AG
- Roquette Frères
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Wacker Chemie AG | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Jungbunzlauer Suisse AG | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Roquette Frères | ✓ | ◐ | − | ✓ | ✓ | ✓ |
| Takasago International Corporation | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Cyclolab Ltd. | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Ashland Global Holdings Inc. | − | ◐ | ✓ | ◐ | ◐ | ◐ |
| Hubei Biocause Pharmaceutical Co. Ltd. | ◐ | ◐ | ◐ | ◐ | − | − |
| Jinan Haohua Industry Co. Ltd. | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Wacker Chemie AG89
2Jungbunzlauer Suisse AG83
3Roquette Frères78
4Takasago International Corporation68
5Cyclolab Ltd.64
6Ashland Global Holdings Inc.60
7Jinan Haohua Industry Co. Ltd.49
8Hubei Biocause Pharmaceutical Co. Ltd.48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Wacker Chemie AGJungbunzlauer Suisse AGRoquette Frères
Challenger1
Strong scale, closing on the leaders.
Takasago International Corporation
Contender2
Focused players with pockets of strength.
Cyclolab Ltd.Ashland Global Holdings Inc.
Niche2
Specialists in a single segment or region.
Hubei Biocause Pharmaceutical Co. Ltd.Jinan Haohua Industry Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Type of Cyclodextrin in North America, then scale across Cyclodextrins in Pharma Market — a $427M beachhead inside a $6.43B market.
Beachhead (SOM)$427Mobtainable near-term
Serviceable (SAM)$2.25Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Alpha-Cyclodextrin
Best fit — highest urgency & budget in Type of Cyclodextrin.
Economic buyer78 fit
Beta-Cyclodextrin
Strong fit — clear ROI and a fast path to value.
End user64 fit
Gamma-Cyclodextrin
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Type of Cyclodextrin in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Type of Cyclodextrin leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cyclodextrins in Pharma Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation13%
Closed-won7%
$21.6KCAC
$82KLTV
3.8:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cyclodextrins in Pharma Market is a high-growth opportunity — $6.12B by 2033, compounding at 10.1%.
TAM · 2025$2.83Btoday
TAM · 2033$6.12Bforecast
CAGR10.1%2027–2033
Cumulative$38.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.12BTotal addressable market
SAM$2.19BServiceable available market
SOM$476MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Type of Cyclodextrin.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Type of Cyclodextrin moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.12BLarge & growingTAM by 2033 at 10.1% CAGR
$2.19BServiceable nowreachable with today’s model
$476MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.77BBear6.6% CAGR
$6.12BBase10.1% CAGR
$7.83BBull13.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cyclodextrins in Pharma Market — a $7.02B market by 2033. Plan: grow share from 11.2% to 18.8%.
Market size · 2033$7.02Btotal addressable
Market CAGR7.2%2027–2033
Target share18.8%from 11.2% today
Revenue ambition$1.32Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.2% | 18.8% | On track |
| Revenue | $814M | $1.32B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.0% | 45.7% | On track |
| Customer retention | 90.9% | 96.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Type of Cyclodextrin
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Type of Cyclodextrin share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $169M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Type of Cyclodextrin leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cyclodextrins in Pharma Market conversation — a $1.00B market you can size, segment and defend in minutes.
Market size · 2033$1.00Btotal opportunity
Growth10.9%CAGR to 2033
Addressable buyers1,130+accounts in scope
Typical ROI5.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Type of Cyclodextrin
Goal Grow share in Type of Cyclodextrin
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.3×return on cost, year one
< 4 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Wacker Chemie AGJungbunzlauer Suisse AGRoquette FrèresTakasago International CorporationCyclolab Ltd.Ashland Global Holdings Inc.Hubei Biocause Pharmaceutical Co. Ltd.Jinan Haohua Industry Co. Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cyclodextrins in Pharma Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cyclodextrins in Pharma Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cyclododecanone (CDON) Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportCyclododecatriene (Cdt) Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportCYCLODODECENE CAS 1501-82-2 Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCycloheptanon Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportCyclohexane (Cx) Market
Market size, share, segmentation and regional forecast.
$650M market · 2025 base year
View reportCyclohexane Ethylene Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportCyclohexanecarboaldehyde Market
Market size, share, segmentation and regional forecast.
$555M market · 2025 base year
View reportCyclohexanecarboxylic acid chloride CAS 2719-27-9 Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCyclohexanhexol Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCyclohexanhexols Market
Market size, share, segmentation and regional forecast.
$899M market · 2025 base year
View reportCyclohexanone oxime CAS 100-64-1 Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCyclohexene oxide CAS 286-20-4 Market
Market size, share, segmentation and regional forecast.
$889M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.